Medindia

X

PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Disinfectant

Thursday, July 10, 2008 General News J E 4
Advertisement
SAN DIEGO, July 10 PURE Bioscience(Nasdaq: PURE) announced today that its distributor in Brazil has obtainednational regulatory approval, recently published in the Brazilian OfficialGazette No. 113, for its silver dihydrogen citrate (SDC)-based disinfectant,"Desinfetante de Uso Geral LFE 100SX."

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

In March 2007, under the terms of a multi-year contract, PURE had granteda license to market and sell its silver dihydrogen citrate (SDC)-basedproducts in Brazil to privately held Life Biociencias S/A of Apucarana, Paranain Brazil (Lifebio), a company of Grupo Nilson Ribeiro, together in a jointventure with privately held PCI International, Inc. of Lafayette, Louisiana(PCI).

Under the agreement, PURE sells concentrate to Lifebio/PCI for blending,packaging and distribution of non-pharmaceutical SDC-based antimicrobialproducts. Lifebio/PCI has constructed a facility in Apucarana, Paranadedicated to blending and packaging SDC concentrate into hard surfacedisinfectant. Lifebio is now poised to begin marketing and sales of itsSDC-based 100SX General Disinfectant.

L. Felippe C. De Castro, President and CEO of PCI stated, "SDC stands onthe cutting edge of innovation by providing unmatched efficacy and safety inthe marketplace, and at the same time, replacing many toxic chemicalscurrently in use. Our partnership with PURE Bioscience brings neededsolutions and presents even greater opportunities within Brazil."

Dr. Nilson Umberto Sacchelli Ribeiro, President of Lifebio and a Directorof Grupo Nilson Ribeiro, added, "Our marketing efforts are well underway andour manufacturing facility is staffed and ready to begin volume production ofSDC-based disinfectant. Our initial targets -- with whom we have been workingclosely -- include federal, state and municipal governments, hospitals andclinics, as well as other institutional users.

"More importantly, as a platform technology, SDC provides a broad range ofapplications for use in farming, ranching, food processing, packing anddistribution and healthcare. To that end, our joint development programs withthe Brazilian ministries of Health and Agriculture are well underway and aremaking solid progress. SDC can drive solutions that bring increasedproductivity, efficiency and growth that cut across virtually all geographicand industry sectors within Brazil."

Michael L. Krall, President and CEO of PURE Bioscience commented,"Receiving regulatory approval is a key milestone for our partners, who willnow begin to introduce product into the world's ninth largest economy.Broadening SDC commercialization for use in health, food and waterapplications gives testimony to Lifebio's foresight in planning and can serveas a model for the integrated utilization and multiple benefits of SDC-basedsolutions."

About PCI International, Inc.

PCI International, Inc. was established in 1981 as an internationalconsulting, trading and government relations firm, with highly specializedexpertise in international trade and economic development. PCI is alwaysprepared to meet the industry's changing needs and toughest challenges. PCIwas formed to provide substantial counsel in international tradeopportunities, to develop International projects and to pursue its clientsbest interests in any given market and its government, specifically in thecountry of Brazil.

About Life Biociencias S/A

Lifebio, established solely to develop and promote silver dihydrogencitrate as a platform technology in Brazil, is a company of Grupo NilsonRibeiro also headquartered in Apucarana, Parana in Brazil. Other companiesunder the Grupo Nilson Ribeiro umbrella include N.A.R. Agropecuaria, EuropeMeat S.p.A., K.Log, Companhia Italo-Brasileira de Produtos Alimenticios,Araguaina Industrial Exportadora de Produtos Alimenticios, King MeatAl
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Major U.S. Health Groups Cite Aspirin Use Among Ot...
S
BioCryst Announces Initiation of Phase II Study of...